Effects of Mirabegron on Beige Fat Activation in Prediabetic Patients
Mechanisms for Activation of Beige Adipose Tissue in Humans
This study is testing if the drug mirabegron can help people with prediabetes by activating a type of fat that may improve their blood sugar levels and overall metabolism.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 65 (estimated) |
| Ages | 35 Years to 65 Years |
| Sex | All |
| Sponsor | University of Kentucky Academic / other |
| Locations | 1 site (Lexington, Kentucky) |
| Trial ID | NCT04666636 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of the drug mirabegron, a specific ß3 adrenergic receptor agonist, on glucose tolerance and adipose tissue in individuals with prediabetes. The study aims to explore how mirabegron can activate beige adipose tissue, which may help improve insulin sensitivity and glucose homeostasis. Participants will be randomly assigned to receive either mirabegron or a placebo, and their metabolic responses will be monitored throughout the trial. The research is based on the premise that activating beige fat could provide a novel approach to managing prediabetes and obesity.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with a BMI between 27 and 45 who have been diagnosed with prediabetes.
Not a fit: Patients with diabetes or those on chronic anti-diabetic medications are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatment options for improving glucose metabolism and preventing the progression of prediabetes.
How similar studies have performed: Previous studies have shown promising results with similar approaches using ß3 adrenergic receptor agonists in obese populations, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI 27-45 * prediabetes (A1c 5.7-6.4) * impaired fasting glucose or impaired glucose tolerance Exclusion Criteria: * diabetes * chronic use of anti-diabetic medication * acute or chronic inflammatory condition * unstable medical condition * cancer * renal insufficiency * any contraindication for Mirabegron * BMI \>45
Where this trial is running
Lexington, Kentucky
- University of Kentucky — Lexington, Kentucky, United States (Recruiting)
Study contacts
- Principal investigator: Philip Kern, MD — University of Kentucky
- Study coordinator: Zach Leicht
- Email: zachary.leicht@uky.edu
- Phone: 859-218-1397
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.